Latest & greatest articles for aspirin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on aspirin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on aspirin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Aspirin

Acetylsalicylic acid (ASA) more commonly known as aspirin is a painkiller that has a wide range of uses. It is frequently used to treat fever, mild pain, tooth aches, headaches and muscle aches. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) and can be used in the management of conditions such as heart attack, arthritis, blood clots and stroke. Aspirin, has been used for thousands of years, initially extracted from the leaves of willow trees.

Aspirin works in much the same way as other NSAIDs but has additional properties, such as antiplatelet activity which can make it additionally useful. More recently aspirin has been linked with cancer prevention. But the potential benefits of aspirin need to be weighed against the potential side effects, which includes gastrointestinal bleeding and Reye’s syndrome. It should be noted that aspirin should not be used in people who are allergic to drugs such as ibuprofen or a more generalized intolerance to NSAIDs. It should also be used cautiously in asthmatics and/or those with bronchospasm associated with NSAID use.

Research evidence, clinical trials and guidelines on Aspirin

The Trip Database has an extensive collection of articles on aspirin ranging from clinical trials, systematic reviews, clinical guidelines and case reports. These can be found via searching the site.

Top results for aspirin

161. Acetylsalicylic acid for venous thromboembolism prophylaxis: an update of clinical evidence

. Acetylsalicylic acid for venous thromboembolism prophylaxis: an update of clinical evidence. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response. 2014 Authors' conclusions Two systematic reviews, two randomized controlled trials, and two non-randomized studies were identified regarding the use of acetylsalicylic acid (ASA) for venous thromboembolism (VTE) prophylaxis in patients undergoing total hip or total knee replacement. Final publication URL Indexing Status Subject (...) Acetylsalicylic acid for venous thromboembolism prophylaxis: an update of clinical evidence Acetylsalicylic acid for venous thromboembolism prophylaxis: an update of clinical evidence Acetylsalicylic acid for venous thromboembolism prophylaxis: an update of clinical evidence CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH

2014 Health Technology Assessment (HTA) Database.

162. Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer. A systematic review and overview of reviews

Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer. A systematic review and overview of reviews Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2013 Health Technology Assessment (HTA) Database.

163. Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews

of Initial Vascular Events ASA acetylsalicylic acid ASCEND A Study of Cardiovascular Events in Diabetes ASPREE Aspirin in Reducing Events in the Elderly ATT Antithrombotic Trialists BDT British Doctors Trial BP blood pressure CARING Chronotherapy with Low-dose Aspirin for Primary Prevention CHD coronary heart disease CI con?dence interval COD cause of death COX cyclo-oxygenase COX-1 cyclo-oxygenase 1 COX-2 cyclo-oxygenase 2 CRC colorectal cancer CRD Centre for Reviews and Dissemination CV cardiovascular (...) Quality assessment of included studies (n=27) 103 Appendix 6 Data extraction 129 Appendix 7 Summaries of included papers and evidence 227 Appendix 8 Revised protocol: 2 September 2012 239 CONTENTS viii NIHR Journals Library www.journalslibrary.nihr.ac.ukList of abbreviations AAA Aspirin for Asymptomatic Atherosclerosis ACCEPT-D Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes APLASA antiphospholipid antibody acetylsalicylic acid ARRIVE Aspirin to Reduce Risk

2013 NIHR HTA programme

164. Should acetylsalicylic acid (ASA) therapy for prevention of thromboembolic events be stopped prior to surgical extractions? Full Text available with Trip Pro

Should acetylsalicylic acid (ASA) therapy for prevention of thromboembolic events be stopped prior to surgical extractions? Randomised controlled trial.Patients with coronary artery disease who were receiving 100 mg/day of ASA for the prevention of thromboembolic events, and requiring at least one molar tooth extracted were randomised to either having their ASA therapy suspended for seven days before tooth extraction and restarted the day following the surgical procedure or not having their ASA (...) therapy suspended at any point before or after the procedure. A single dentist who was unaware of the patients' ASA therapy status performed all the extractions.Outcomes were a platelet aggregation test carried out on the day of the operation and the amount of bleeding measured during the intra-operative period.Bleeding was controlled with local haemostatic methods and there were no reported episodes of haemorrhaging during the intra- and post-operative periods. The mean (±SD) volume of bleeding

2013 Evidence-based dentistry Controlled trial quality: uncertain

165. Codeine and Acetylsalicylic Acid for the Management of Post-Tonsillectomy or Adenoidectomy Pain

following tonsillectomy and/or adenoidectomy. 7,8 Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen can be used for pain control, while the use of acetylsalicylic acid (ASA) and ketorolac may associated with increase bleeding. 4,9 The findings of a recent systematic review showed that NSAIDs did not result in any increase in bleeding in pediatric tonsillectomy. 10 The NSAIDs in the review included ketoprofen, ketorolac, ibuprofen, diclofenac, rofecoxib and tenoxicam. 10 However, ASA (...) Codeine and Acetylsalicylic Acid for the Management of Post-Tonsillectomy or Adenoidectomy Pain TITLE: Codeine and Acetylsalicylic Acid for the Management of Post-Tonsillectomy or Adenoidectomy Pain: A Review of the Clinical Evidence DATE: 20 June 2013 CONTEXT AND POLICY ISSUES Tonsils are lymphoid tissues located at the back of the throat, while adenoids are made of tissue located at the back of the nose near the throat (nasopharynx). Recurrent infections may cause enlargement of these tissues

2013 Canadian Agency for Drugs and Technologies in Health - Rapid Review

166. Aspirin use and risk of colorectal cancer according to BRAF mutation status. Full Text available with Trip Pro

Aspirin use and risk of colorectal cancer according to BRAF mutation status. Aspirin use reduces the risk of colorectal carcinoma. Experimental evidence implicates a role of RAF kinases in up-regulation of prostaglandin-endoperoxide synthase 2 (PTGS2, cyclooxygenase 2), suggesting that BRAF-mutant colonic cells might be less sensitive to the antitumor effects of aspirin than BRAF-wild-type neoplastic cells.To examine whether the association of aspirin intake with colorectal cancer risk differs (...) according to status of tumor BRAF oncogene mutation.We collected biennial questionnaire data on aspirin use and followed up participants in the Nurses' Health Study (from 1980) and the Health Professionals Follow-up Study (from 1986) until July 1, 2006, for cancer incidence and until January 1, 2012, for cancer mortality. Duplication-method Cox proportional cause-specific hazards regression for competing risks data was used to compute hazard ratios (HRs) for colorectal carcinoma incidence according

2013 JAMA

167. Effect of low-dose aspirin on functional outcome from cerebral vascular events in women Full Text available with Trip Pro

Effect of low-dose aspirin on functional outcome from cerebral vascular events in women Although aspirin is effective in prevention of stroke, fewer studies have examined the impact of aspirin on stroke morbidity.The Women's Health Study is a completed randomized, placebo-controlled trial designed to test the effect of low-dose aspirin and vitamin E in the primary prevention of cardiovascular disease and cancer, which enrolled 39 876 women. We used multinomial logistic regression to evaluate (...) the relationship between randomized aspirin assignment and functional outcomes from stroke. Possible functional outcomes were neither stroke nor transient ischemic attack (TIA), modified Rankin scale (mRS) score 0 to 1, 2 to 3, and 4 to 6.After a mean of 9.9 years of follow-up, 460 confirmed strokes (366 ischemic, 90 hemorrhagic, and 4 unknown type) and 405 confirmed TIAs occurred. With regard to total and ischemic stroke, women who were randomized to aspirin had a nonsignificant decrease in risk of any

2013 EvidenceUpdates Controlled trial quality: predicted high

168. Aspirin did not reduce recurrence after a first-ever, unprovoked venous thromboembolism. Full Text available with Trip Pro

Aspirin did not reduce recurrence after a first-ever, unprovoked venous thromboembolism. 23552619 2013 05 13 2013 04 04 1539-3704 158 6 2013 Mar 19 Annals of internal medicine Ann. Intern. Med. ACP Journal Club. Aspirin did not reduce recurrence after a first-ever, unprovoked venous thromboembolism. JC2 10.7326/0003-4819-158-6-201303190-02002 Deloughery Thomas T eng Comment Journal Article United States Ann Intern Med 0372351 0003-4819 N Engl J Med. 2012 Nov 22;367(21):1979-87 23121403 2013 4 5

2013 Annals of Internal Medicine

169. Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable

Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable Coleman CI, Straznitskas AD, Sobieraj DM, Kluger J, Anglade MW Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of clopidogrel plus aspirin, compared with aspirin alone, for the prevention of stroke in patients with uncomplicated atrial fibrillation. The authors concluded

2013 NHS Economic Evaluation Database.

170. Effect of acetylsalicylic acid usage and platelet transfusion on postoperative hemorrhage and activities of daily living in patients with acute intracerebral hemorrhage Full Text available with Trip Pro

Effect of acetylsalicylic acid usage and platelet transfusion on postoperative hemorrhage and activities of daily living in patients with acute intracerebral hemorrhage The authors evaluated the effects of acetylsalicylic acid (ASA) usage and transfusion of previously frozen apheresis platelets on postoperative hemorrhage, activities of daily living (ADL) score, and mortality rate in patients with acute hypertensive basal ganglia hemorrhage undergoing craniotomy.This was a prospective, double (...) -blind, parallel, randomized controlled trial in patients with acute hypertensive basal ganglia hemorrhage, who had either not received ASA therapy (control) or received ASA therapy. The patients who received ASA therapy were divided according to the results of a platelet aggregation test into ASA-resistant, ASA-semiresponsive, and ASA-sensitive groups. All patients required an emergency craniotomy for hematoma removal after hospitalization. The patients who were sensitive to ASA were randomized

2013 EvidenceUpdates Controlled trial quality: uncertain

171. WARFASA: Aspirin for Preventing the Recurrence of Venous Thromboembolism

WARFASA: Aspirin for Preventing the Recurrence of Venous Thromboembolism RXFILES TRIAL SUMMARY MATTHEW SWANKHUIZEN – MAY 2013 – WWW.RXFILES.CA Page 1 of 2 WARFASA: Aspirin for Preventing the Recurrence of Venous Thromboembolism 1 WARFarin and AcetylSalicylic Acid Study BOTTOM LINE • In patients whom have had a first unprovoked VTE with low to moderate bleed risk, the addition of ASA 100 mg daily is reasonable to prevent future DVT not PE or mortality events, if the decision is made to stop VKA (...) ° outcome of arterial event ?Method for diagnosis of recurrent DVT venous compression ultrasonography has a false positive rate of 14% which may have accounted for observed difference ?Slow recruitment of patients took 6 years to complete ?Small very specific sample size UNCERTAINITIES: ?Applicability to non-caucasian individuals ?2012 Chest guidelines suggest VKA therapy for 3 months but minimum in this study was 6 months 2 k =male,2°=Secondary, ARR=Absolute risk reduction, ASA=Acetylsalicylic Acid

2013 RxFiles

172. ASPIRE: Low?Dose Aspirin for Preventing Recurrent Venous Thromboembolism

°=Secondary, ARR=Absolute risk reduction, ASA=Acetylsalicylic Acid, CHD=Coronary heart disease, CVD=Cerebrovascular disease, CV= Cardiovascular,CI=Confidence interval, DVT=Deep vein thrombosis, HR= Harm Ratio,GI=Gastrointestinal, HRT=Hormone replacement therapy, ITT=Intention to treat,INR=International normalized ratio, MI=Myocardial Infarction, NR=Not reported, NS=Non-significant, NNT=Number needed to treat,NNH=Number needed to harm, NSAID= Non-steroidal anti-inflammatory drug, PE=Pulmonary embolism, PUD (...) ASPIRE: Low?Dose Aspirin for Preventing Recurrent Venous Thromboembolism RXFILES TRIAL SUMMARY MATTHEW SWANKHUIZEN – MAY 2013 – WWW.RXFILES.CA Page 1 of 2 ASPIRE: Low-Dose Aspirin for Preventing Recurrent Venous Thromboembolism 1 Aspirin to Prevent Recurrent Venous Thromboembolism BOTTOM LINE • In patients whom have had an unprovoked VTE with low to moderate bleed risk the addition of ASA 100 mg daily is reasonable to prevent future VTE events and major vascular events if the decision is made

2013 RxFiles

173. Cohort study: Lack of association between proton pump inhibitors and adverse events in patients taking clopidogrel and aspirin

Cohort study: Lack of association between proton pump inhibitors and adverse events in patients taking clopidogrel and aspirin Lack of association between proton pump inhibitors and adverse events in patients taking clopidogrel and aspirin | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Lack of association between proton pump inhibitors and adverse events in patients taking clopidogrel and aspirin Article Text Aetiology Cohort study Lack

2013 Evidence-Based Medicine

174. Ischaemic stroke: sometimes thrombolysis and very often aspirin

Ischaemic stroke: sometimes thrombolysis and very often aspirin Prescrire IN ENGLISH - Spotlight ''Ischaemic stroke: sometimes thrombolysis and very often aspirin '', 1 November 2013 {1} {1} {1} | | > > > Ischaemic stroke: sometimes thrombolysis and very often aspirin Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Ischaemic stroke: sometimes (...) thrombolysis and very often aspirin In the acute phase of an ischaemic stroke, some patients benefit from thrombolysis when it is administered within 3 hours. Most patients are treated with aspirin. Some 80% of strokes are of ischaemic origin (blocked vessels). Around 12% of patients die within the three months following the stroke, and 20% remain in an institution or are highly dependent. When a person shows symptoms of a stroke, it is advisable to get them to hospital as quickly as possible so they can

2013 Prescrire

175. Vitamin E in Combination With Aspirin Can Pose Potential Postoperative Bleeding

anti-platelet effect of aspirin in combination with vitamin E. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Celestini/2002 Healthy Human (blood) taking no medication. In vitro study Key results The anti-platelet aggregation effect of acetylsalicylic acid was enhanced in presence of vitamin E, by increasing the NO(nitrous oxide) production 42 fold(P #2) Gonzalez-Correa/2005 Whole blood from healthy (...) Surgery) (Periodontics) (Dental Hygiene) Keywords Vitamin E, Acetylsalicylic acid, collagen, antiplatelet aggregation ID# 2440 Date of submission: 04/01/2013 E-mail Heydaris3@livemail.uthscsa.edu Author Soulmaz Heydari Co-author(s) Co-author(s) e-mail Faculty mentor/Co-author Gregory Spackman, DDS, MBA Faculty mentor/Co-author e-mail spackman@uthscsa.edu Basic Science Rationale (Mechanisms that may account for and/or explain the clinical question, i.e. is the answer to the clinical question consistent

2013 UTHSCSA Dental School CAT Library

176. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. Full Text available with Trip Pro

Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. Stroke is common during the first few weeks after a transient ischemic attack (TIA) or minor ischemic stroke. Combination therapy with clopidogrel and aspirin may provide greater protection against subsequent stroke than aspirin alone.In a randomized, double-blind, placebo-controlled trial conducted at 114 centers in China, we randomly assigned 5170 patients within 24 hours after the onset of minor ischemic stroke (...) or high-risk TIA to combination therapy with clopidogrel and aspirin (clopidogrel at an initial dose of 300 mg, followed by 75 mg per day for 90 days, plus aspirin at a dose of 75 mg per day for the first 21 days) or to placebo plus aspirin (75 mg per day for 90 days). All participants received open-label aspirin at a clinician-determined dose of 75 to 300 mg on day 1. The primary outcome was stroke (ischemic or hemorrhagic) during 90 days of follow-up in an intention-to-treat analysis. Treatment

2013 NEJM Controlled trial quality: predicted high

177. Randomised controlled trial: Aspirin given for up to 2?years after initial anticoagulant treatment reduces the risk of venous thromboembolism recurrence without increasing risk of major bleeding Full Text available with Trip Pro

Randomised controlled trial: Aspirin given for up to 2?years after initial anticoagulant treatment reduces the risk of venous thromboembolism recurrence without increasing risk of major bleeding Aspirin given for up to 2 years after initial anticoagulant treatment reduces the risk of venous thromboembolism recurrence without increasing risk of major bleeding | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your (...) cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Aspirin given for up to 2 years

2013 Evidence-Based Nursing

178. First update of the current evidence for the management of ankylosing spondylitis with non-pharmacological treatment and non-biologic drugs: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis (Abstract)

First update of the current evidence for the management of ankylosing spondylitis with non-pharmacological treatment and non-biologic drugs: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis To perform a systematic literature review as a basis for the update of the Assessment in SpondyloArthritis International Society and European League Against Reumatism (ASAS/EULAR) recommendations for the management of AS with non-pharmacological (...) including coxibs improve BASDAI, disease activity and BASFI. No effect of SSZ and MTX on any variable was found. Surgical interventions of the spine and the hip can give excellent results by restoring function.This concise summary of current evidence for non-pharmacological interventions and non-biologic drugs formed the basis for the update of the ASAS/EULAR recommendations for the management of AS.

2013 EvidenceUpdates

179. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. (Abstract)

Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. If percutaneous coronary intervention (PCI) is required in patients taking oral anticoagulants, antiplatelet therapy with aspirin and clopidogrel is indicated, but such triple therapy increases the risk of serious bleeding. We investigated the safety and efficacy of clopidogrel alone compared with clopidogrel (...) plus aspirin.We did an open-label, multicentre, randomised, controlled trial in 15 centres in Belgium and the Netherlands. From November, 2008, to November, 2011, adults receiving oral anticoagulants and undergoing PCI were assigned clopidogrel alone (double therapy) or clopidogrel plus aspirin (triple therapy). The primary outcome was any bleeding episode within 1 year of PCI, assessed by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00769938.573 patients were

2013 Lancet Controlled trial quality: predicted high

180. Systematic review with meta-analysis: Aspirin prophylaxis in people without prior cardiovascular disease does not lead to reductions in cardiovascular death or cancer mortality

Systematic review with meta-analysis: Aspirin prophylaxis in people without prior cardiovascular disease does not lead to reductions in cardiovascular death or cancer mortality Aspirin prophylaxis in people without prior cardiovascular disease does not lead to reductions in cardiovascular death or cancer mortality | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time (...) . To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Aspirin prophylaxis in people without prior cardiovascular disease does

2013 Evidence-Based Medicine